Nanjing Leads Biolabs’ LBL-034 Secures Clinical Trial Approvals from NMPA and FDA
Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced receiving clinical trial approvals...
Drug
Huadong Medicine Receives NMPA Approval for Phase I Clinical Trial of DR10624 for Weight Management
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Akeso Biopharma Initiates Phase Ia/Ib Study for TIGIT mAb AK127 in Solid Tumors Combination Therapy
China-based Akeso Biopharma (HKG: 9926) has announced the first patient enrollment in a Phase Ia/Ib...
Eli Lilly’s Tirzepatide Demonstrates Up to 26.6% Weight Loss in Phase III Obesity Studies
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has released final results from two...
Sino Biopharmaceutical Receives NMPA Approval for Biosimilar Herceptin for HER2+ Cancers
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received market approval from the...
Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of...
Jiangsu Simcere Pharmaceutical Receives NMPA Approval for Atopic Dermatitis Drug SIM0278
China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received clinical...
CanSino Biotechnology Receives NMPA Approval for Tetanus Vaccine CS-2047
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced that it has received clinical...
BRL Medicine Inc. Receives IND Approval for CD19-Targeted CAR-T Therapy BRL-301 from CDE
Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...
MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials
Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase...
Everest Medicines Launches Xerava Antibiotic in China, Marking Commercial Milestone
Everest Medicines (HKG: 1952) has announced the commercial launch of its Xerava (eravacycline) antibiotic in...
Jiangsu Recbio’s Shingles Vaccine REC610 Accepted for Review by China’s NMPA
Jiangsu Recbio Technology Co., Ltd, a China-based company, has announced that the National Medical Products...
Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....
SSY Group Ltd Receives NMPA Approval for Stiripentol Dry Suspension for Dravet Syndrome
China-based SSY Group Ltd (HKG: 2005) has announced that it has received marketing approval from...
Novo Nordisk’s Turoctocog Alfa Pegol for Hemophilia A Accepted for Review by China’s CDE
The Center for Drug Evaluation (CDE) in China has indicated on its website that the...
AstraZeneca’s Eplontersen Gains Tacit Approval from CDE for ATTR-CM Clinical Study
The Center for Drug Evaluation (CDE) website indicates that UK pharmaceutical major AstraZeneca’s (AZ, NASDAQ:...
Boehringer Ingelheim Gets NMPA Approval for Phase II Study of BI 764532 in SCLC
Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical Products...
HanchorBio’s HCB101 Receives WFDA Approval for Multi-Region Clinical Study
Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug...
InnoCare Pharma’s ICP-723 Receives NMPA Approval for Pediatric Clinical Study
Beijing InnoCare Pharma (HKG: 9969), a China-based biotech company specializing in cancer and autoimmune diseases,...